SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Intestinal Research
; : 171-183, 2022.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-925133
Responsible library:
WPRO
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.8 Achieve universal access to health
Database:
WPRIM (Western Pacific)
Type of study:
Practice guideline
Language:
English
Journal:
Intestinal Research
Year:
2022
Document type:
Article